← All Galecto, INC filings

Galecto, INC Schedule 13D activist filings

Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.

GLTO
Galecto, INC
SCHEDULE: Fairmount Funds Boosts Galecto Stake to 19.99%
Fairmount Funds Management LLC and its affiliates increased their beneficial ownership in Galecto, Inc. to 19.99% following the conversion of Series C Preferred Stock.
GLTO
Galecto, INC
SCHEDULE: Fairmount Funds Boosts Galecto Stake to 19.99% Post-Damora Merger
Fairmount Funds Management and its affiliates have reported a 19.99% beneficial ownership in Galecto, Inc. following the acquisition of Damora Therapeutics and a $285 million PIPE financing.
GLTO
Galecto, INC
SCHEDULE: Novo Holdings Exits Galecto, Sells All Shares
Novo Holdings A/S has fully divested its stake in Galecto, Inc., ceasing to be a beneficial owner of more than five percent of the common stock.
GLTO
Galecto, INC
SCHEDULE: Novo Holdings Reduces Galecto Stake to 6.5%
Novo Holdings A/S has filed an Amendment No. 4 to its Schedule 13D, reporting a reduction in its beneficial ownership of Galecto, Inc. common stock to 6.5% after selling 13,334 shares.
GLTO
Galecto, INC
SCHEDULE 13D/A: Novo Holdings A/S Updates Galecto, Inc. Stake to 7.6% Following Reverse Stock Split
Novo Holdings A/S has filed an amendment to its Schedule 13D, reporting a 7.6% beneficial ownership in Galecto, Inc. after a 1-for-25 reverse stock split and an increase in outstanding shares.